Novartis reported Phase 3 results showing its ganaplacide-based combination therapy (GanLum) achieved cure rates that exceed the World Health Organization’s 95% threshold in trials across sub‑Saharan Africa. The company said the regimen was non‑inferior to standard artemisinin‑based therapies in a 1,688‑patient study and showed activity against strains with artemisinin resistance. Novartis framed the data as positioning GanLum for rapid regulatory submissions and deployment against rising drug resistance. The trial was run with Medicines for Malaria Venture partners at multiple sites in Africa; Novartis highlighted both symptomatic clearance and potential transmission‑blocking activity. Regulators and global health groups will weigh efficacy against safety and manufacturing scale as Novartis pursues approvals. Clarification: ganaplacide is a novel antimalarial targeting parasite protein transport pathways to act at multiple life stages of Plasmodium.